RG-3039

Modify Date: 2024-01-03 11:47:31

RG-3039 Structure
RG-3039 structure
Common Name RG-3039
CAS Number 1005504-62-0 Molecular Weight 432.346
Density 1.4±0.1 g/cm3 Boiling Point 648.1±65.0 °C at 760 mmHg
Molecular Formula C21H23Cl2N5O Melting Point N/A
MSDS N/A Flash Point 345.8±34.3 °C

 Use of RG-3039


RG3039 (PF-06687859) is an orally bioavailable and brain-penetrant DcpS inhibitor with an IC50 of 0.069 nM.

 Names

Name 5-[[1-[(2,6-dichlorophenyl)methyl]piperidin-4-yl]methoxy]quinazoline-2,4-diamine
Synonym More Synonyms

 RG-3039 Biological Activity

Description RG3039 (PF-06687859) is an orally bioavailable and brain-penetrant DcpS inhibitor with an IC50 of 0.069 nM.
Related Catalog
Target

IC50: 0.069 nM (DcpS)[1]

In Vitro RG3039 is a dibasic lipophilic molecule that is predicted to accumulate in lysosomes[1]. In motor neurons, RG3039 significantly increases both the average number of cells with gems and average number of gems per cell, which is used as an indirect measure of SMN levels[2].
In Vivo RG3039 can extend survival and improve function in two SMA mouse models of varying disease severity (Taiwanese 5058 Hemi and 2B/− SMA mice), and positively impacts neuromuscular pathologies. In 2B/− SMA mice, RG3039 provides a >600% survival benefit (median 18 days to >112 days) when dosing began at P4, highlighting the importance of early intervention[2]. RG3039 distributes to central nervous system tissues where it robustly inhibits DcpS enzyme activity, but minimally activates SMN expression or the assembly of small nuclear ribonucleoproteins. RG3039 treated SMA mice shows a dose-dependent increase in survival, weight and motor function and it is associated with improved motor neuron somal and neuromuscular junction synaptic innervation and function and increased muscle size. RG3039 also enhances survival of conditional SMA mice in which SMN has been genetically restored to motor neurons[3].
Animal Admin Mice: Mice receive intraperitoneal (i.p.) injections of RG3039 starting on post natal day 1 (P1) defined as the day of birth. All treated litters are culled at P4 to a total of six pups. Daily weights and righting-time are determined starting on P1. Ambulation index is performed between P13 and P23. A compilation score is determined during two 60 s trials[3].
References

[1]. Gopalsamy A, et al. Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA). J Med Chem. 2017 Apr 13;60(7):3094-3108.

[2]. Gogliotti RG, et al. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet. 2013 Oct 15;22(20):4084-101.

[3]. Van Meerbeke J, et al. The DcpS inhibitor RG3039 improves motor function in SMA mice. Hum Mol Genet. 2013 Oct 15;22(20):4074-83.

 Chemical & Physical Properties

Density 1.4±0.1 g/cm3
Boiling Point 648.1±65.0 °C at 760 mmHg
Molecular Formula C21H23Cl2N5O
Molecular Weight 432.346
Flash Point 345.8±34.3 °C
Exact Mass 431.127960
PSA 91.75000
LogP 4.25
Vapour Pressure 0.0±1.9 mmHg at 25°C
Index of Refraction 1.682
Storage condition 2-8℃

 Synonyms

unii-ksv93l7urw
5-{[1-(2,6-Dichlorobenzyl)-4-piperidinyl]methoxy}-2,4-quinazolinediamine
2,4-Quinazolinediamine, 5-[[1-[(2,6-dichlorophenyl)methyl]-4-piperidinyl]methoxy]-
PF-06687859
RG-3039
RG3039
Top Suppliers:I want be here



Get all suppliers and price by the below link:

RG-3039 suppliers


Price: $79/10mM*1mLinDMSO

Reference only. check more RG-3039 price